BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36004713)

  • 1. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
    Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
    Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
    Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ
    World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
    Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
    Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H
    J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
    Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.
    Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M;
    Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
    Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
    J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.
    Liu S; Deng R; Zhou B; Liang X; Liu Z; Peng J; Chen J; Zhou Y; Guo Y; Chen Y; Li W; Shen S; Lu X; Zhao S; Liao X; Liang H; Lan Y; Hou J; Fan R; Sun J
    J Infect Dis; 2022 Sep; 226(5):881-890. PubMed ID: 34931674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
    Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA.
    Lee HA; Lee YS; Jung YK; Kim JH; Yim HJ; Yeon JE; Seo YS; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 May; 38(5):716-723. PubMed ID: 36681856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy.
    Lin CL; Tseng KC; Chen KY; Liao LY; Kao JH
    J Formos Med Assoc; 2020 Oct; 119(10):1483-1489. PubMed ID: 32653388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
    Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
    Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Level of Hepatitis B Viremia Compared With Undetectable Viremia Increases the Risk of Hepatocellular Carcinoma in Patients With Untreated Compensated Cirrhosis.
    Yang J; Choi WM; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Choi J
    Am J Gastroenterol; 2023 Jun; 118(6):1010-1018. PubMed ID: 36622283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
    Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
    Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.
    Kumada T; Toyoda H; Yasuda S; Miyake N; Ito T; Tanaka J
    J Viral Hepat; 2021 Mar; 28(3):508-516. PubMed ID: 33306854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.